Therapeutic apheresis in myasthenia gravis patients: a six year follow-up.
Six years ago 4 patients suffering from myasthenia gravis (MG) types C and E according to Compston with failed drug therapy were initially treated 3 times (1 patient, a total of 11 times) by protein A immunoadsorption (Immunosorba, Excorim AB, Lund, Sweden). No further immunoadsorption treatments have been carried out. In addition, 3 patients were given a thymectomy. The present status of the patients was checked. We could see a beneficial effect in all MG patients. The patients are fit for work; each has an improved Besinger index. The patients were used as their own controls. A higher anti-AChRAb level 6 years after protein A immunoadsorption than at the beginning was seen in all patients, combined with less serious MG. In addition, their immunomodulation could be induced as seen in lymphocyte and inflammatory protein changes during the first 36 days after beginning immunoadsorption treatment. A larger population has to be investigated to verify these results.
Schneidewind
J M
JM
Dialysis Community North r.s., Rostock, Germany.
Zettl
U K
UK
Winkler
R E
RE
Ramlow
W
W
Tiess
M
M
Hofmann
D
D
Michelsen
A
A
Weber
G
G
Kinze
E M
EM
Adam
U
U
Hauk
L
L
Behnecke
R
R
Klinkmann
H
H
D000328:Adult; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007163:Immunosorbent Techniques; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000175:diagnosis / Q000628:therapy*; D010956:Plasmapheresis / Q000009:adverse effects / Q000379:methods*; D012680:Sensitivity and Specificity; D013205:Staphylococcal Protein A / Q000627:therapeutic use*; D016896:Treatment Outcome
D013205:Staphylococcal Protein A